Tendencias Ahora
Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.
¿Ya eres miembro? Iniciar sesión
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). Mostrar más
Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
---|---|---|---|---|---|---|---|---|
1 | 0.31 | 4.55882352941 | 6.8 | 8.37 | 6.67 | 56649 | 7.69032922 | CS |
4 | -0.01 | -0.140449438202 | 7.12 | 8.37 | 6.02 | 37058 | 7.31396782 | CS |
12 | -1.41 | -16.5492957746 | 8.52 | 11.1261 | 6.02 | 30684 | 7.93988804 | CS |
26 | 0.84 | 13.3971291866 | 6.27 | 11.1261 | 6.02 | 44392 | 8.09982841 | CS |
52 | 2.11 | 42.2 | 5 | 11.1261 | 5 | 27465 | 8.04998811 | CS |
156 | 2.11 | 42.2 | 5 | 11.1261 | 5 | 9118 | 8.04998811 | CS |
260 | 2.11 | 42.2 | 5 | 11.1261 | 5 | 6073 | 8.04998811 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones